News
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in September.
CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell. After that ...
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
The CRISPR gene editing technology has transformed the research lab, and this powerful tool is now making its way into the clinic. So far, three different human diseases have been successfully ...
DAVIS, CALIF. — Scientists at the University of California, Davis, have developed wheat plants that stimulate production of its own fertilizer, which could bring environmental and cost-reduction ...
News Medical on MSN16d
New CRISPR technique could rewrite future of genetic disease treatment
A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like Sickle Cell, while also proving beyond doubt that chemical tags on DNA — often ...
The global CRISPR-based gene editing market size is projected to grow from USD 4.46 billion in 2025 to over USD 13.39 billion by 2034, expanding at a CAGR of 13%. Growth is fueled by advancements in ...
Scientists have achieved the first DNA-free CRISPR gene editing in raspberries, reaching 19% efficiency and opening the door to faster breeding of firmer, more resilient berries — though regenerating ...
Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in ...
U.S. Gene Editing Market to Expand from USD 1.95 Billion in 2024 to USD 4.82 Billion by 2032, Driven by Growing Therapeutic Applications, Federal Research Funding, and Biotech Investments.Austin, Sept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback